CoChat

Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC

Open access
Yang, Yanping, Ye, Maosong, Song, Yijun, Xing, Wenyu, Zhao, Xing, Li, Yufan, Shen, Jiacheng, Zhou, Jian, Arikawa, Kinji, Wu, Shengdi, Song, Yuanlin, Xu, Nuo · 2025 · npj Biofilms and Microbiomes

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

The role of gut dysbiosis in shaping immunotherapy responses is well-recognized, yet its effect on the therapeutic efficacy of chemotherapy and immunotherapy combinations remains poorly understood. We analyzed gut microbiota in non-small cell lung cancer (NSCLC) patients treated with chemo-immunotherapy, comparing responders and non-responders using 16S rRNA sequencing. Responders showed higher microbial richness and abundance of specific genera like Faecalibacterium and Subdoligranulum, and the phylum Firmicutes. Support vector machine (SVM), a machine learning model based on microbial composition, predicted treatment efficacy with the area under the curve (AUC) values of 0.763 for genera and 0.855 for species. Metagenomic analysis revealed significant differences in metabolic pathways, with responders exhibiting higher short-chain fatty acids (SCFAs) production. Fecal microbiota transplantation (FMT) and SCFAs supplementation in mouse models enhanced treatment efficacy by promoting effector T cell activity in tumors. Our study suggests that gut microbiota, through SCFAs production, regulates chemo-immunotherapy efficacy, offering new strategies to improve NSCLC treatment outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41522-025-00785-9

Cites

38 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Significant difference in diversity between responders (R) and non-responders (NR) groups. The Shannon (A), Simpson (B), and Chao (C) analyses showed significantly lower OUT richness and evenness in the NR group compared to the R group. Principal coordinates analysis (PCoA) based on Bray-Curtis (D) and partial least squares discriminant analysis (PLS-DA) (PLS-DA) (E) indicated that the microbiota composition of the R group clusters varied significantly from that of the NR group. F The Venn diagram highlighted the differences between the two groups at the genus level. G Genera identified via 16S rRNA sequencing in the R and NR groups. H Analysis of the differences in gut microbiota composition and dominant microbiota among the two groups at the genus level. *P < 0.05, **P < 0.01.
Fig. 1 Significant difference in diversity between responders (R) and non-responders (NR) groups. The Shannon (A), Simpson (B), and Chao (C) analyses showed significantly lower OUT richness and evenness in the NR group compared to the R group. Principal coordinates analysis (PCoA) based on Bray-Curtis (D) and partial least squares discriminant analysis (PLS-DA) (PLS-DA) (E) indicated that the microbiota composition of the R group clusters varied significantly from that of the NR group. F The Venn diagram highlighted the differences between the two groups at the genus level. G Genera identified via 16S rRNA sequencing in the R and NR groups. H Analysis of the differences in gut microbiota composition and dominant microbiota among the two groups at the genus level. *P < 0.05, **P < 0.01.CC BY-NC-ND · PubMed Central
Fig. 2 Correlation between clinical parameters and gut microbiota. A Relationship between immune cell levels and gut microbiota. B Relationship between cytokine levels and gut microbiota. Colors in the figure notes: red represents high coefficient and positive correlation, green represents low coefficient and negative correlation. Values: Correlation coefficient between the dominant microbiota and clinical parameters, with a higher coefficient indicating higher correlation and a lower coefficient indicating lower correlation. C Detailed annotation of clinical parameters. *P < 0.05, **P < 0.01.
Fig. 2 Correlation between clinical parameters and gut microbiota. A Relationship between immune cell levels and gut microbiota. B Relationship between cytokine levels and gut microbiota. Colors in the figure notes: red represents high coefficient and positive correlation, green represents low coefficient and negative correlation. Values: Correlation coefficient between the dominant microbiota and clinical parameters, with a higher coefficient indicating higher correlation and a lower coefficient indicating lower correlation. C Detailed annotation of clinical parameters. *P < 0.05, **P < 0.01.CC BY-NC-ND · PubMed Central
Fig. 3 Different bacterial composition between responders (R) and non-responders (NR) groups. A Linear discriminant analysis Effect Size (LEfSe) analysis revealed different gut microbiota detected in R and NR groups. B–M Comparative analysis of gut bacterial genera between R and NR groups at the genus level (*P < 0.05, **P < 0.01).
Fig. 3 Different bacterial composition between responders (R) and non-responders (NR) groups. A Linear discriminant analysis Effect Size (LEfSe) analysis revealed different gut microbiota detected in R and NR groups. B–M Comparative analysis of gut bacterial genera between R and NR groups at the genus level (*P < 0.05, **P < 0.01).CC BY-NC-ND · PubMed Central
Fig. 4 Receiver operating curves (ROC) for gut microbiota predicting chemo-immunotherapy combination treatment efficacy. A Top 20 bacteria of importance at the genus level. B ROC curve of the top 20 bacteria of importance at the genus level. C Top 20 bacteria of importance at the species level. D ROC curve of the top 20 bacteria of importance at the species level.
Fig. 4 Receiver operating curves (ROC) for gut microbiota predicting chemo-immunotherapy combination treatment efficacy. A Top 20 bacteria of importance at the genus level. B ROC curve of the top 20 bacteria of importance at the genus level. C Top 20 bacteria of importance at the species level. D ROC curve of the top 20 bacteria of importance at the species level.CC BY-NC-ND · PubMed Central
Fig. 5 Metagenomic analysis showing the difference in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and KEGG Orthologous (KO) between responders (R) and non-responders (NR) groups. A Principal coordinate analysis (PCoA) showing distinct distribution of gut functional differences between the R and NR groups. B–D Differences in KEGG pathway levels 1, 2, and 3 (KO) between the R and NR groups. *P < 0.05, **P < 0.01.
Fig. 5 Metagenomic analysis showing the difference in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and KEGG Orthologous (KO) between responders (R) and non-responders (NR) groups. A Principal coordinate analysis (PCoA) showing distinct distribution of gut functional differences between the R and NR groups. B–D Differences in KEGG pathway levels 1, 2, and 3 (KO) between the R and NR groups. *P < 0.05, **P < 0.01.CC BY-NC-ND · PubMed Central
Fig. 6 The difference in abundance of short-chain fatty acids (SCFAs) in responders (R) and non-responders (NR) groups and its association with gut microbiota. A Z-score of each SCFA in the R and NR groups. B–J The abundance of acetic, isovaleric, valeric, hexanoic, and isobutyric acid between the two groups, among which the levels of total SCFAs, butanoic and propanoic acid were significantly elevated in the R group, compared with the NR groups. K The relationship between each SCFA and gut microbiota. *P < 0.05, **P < 0.01.
Fig. 6 The difference in abundance of short-chain fatty acids (SCFAs) in responders (R) and non-responders (NR) groups and its association with gut microbiota. A Z-score of each SCFA in the R and NR groups. B–J The abundance of acetic, isovaleric, valeric, hexanoic, and isobutyric acid between the two groups, among which the levels of total SCFAs, butanoic and propanoic acid were significantly elevated in the R group, compared with the NR groups. K The relationship between each SCFA and gut microbiota. *P < 0.05, **P < 0.01.CC BY-NC-ND · PubMed Central
Fig. 7 Enhanced anti-tumor efficacy of combined therapy by gut microbiota and short-chain fatty acids (SCFAs) in tumor-bearing mice. A Schematic diagram of mouse experiments. B Tumor volume changes in the antibiotic treatment (ABX) group, ABX+ fecal microbiota transplantation (FMT) group, and ABX+SCFAs group (n = 5 per group). Tumor volume was measured every three days starting on Day 9 of tumor inoculation. Statistical differences were examined using two-way analysis of variance (ANOVA). *P < 0.05, ****P < 0.0001, ####P < 0.0001. C Changes in tumor weight of mice in ABX group, ABX + FMT group, and ABX+SCFAs group. Statistical differences were examined using one-way ANOVA. *P < 0.05, **P < 0.01.
Fig. 7 Enhanced anti-tumor efficacy of combined therapy by gut microbiota and short-chain fatty acids (SCFAs) in tumor-bearing mice. A Schematic diagram of mouse experiments. B Tumor volume changes in the antibiotic treatment (ABX) group, ABX+ fecal microbiota transplantation (FMT) group, and ABX+SCFAs group (n = 5 per group). Tumor volume was measured every three days starting on Day 9 of tumor inoculation. Statistical differences were examined using two-way analysis of variance (ANOVA). *P < 0.05, ****P < 0.0001, ####P < 0.0001. C Changes in tumor weight of mice in ABX group, ABX + FMT group, and ABX+SCFAs group. Statistical differences were examined using one-way ANOVA. *P < 0.05, **P < 0.01.CC BY-NC-ND · PubMed Central
Fig. 8 Enhanced anti-tumor immune response by gut microbiota and short-chain fatty acids (SCFAs). A, B Flow cytometry to detect the immune cells in the spleen and tumors (n = 5 per group). Infiltration of CD45+ T cells, CD3+ T cells, CD8+ T cells, and the expression of tumor necrosis factor-α (TNF-α), granzyme B (GZMB) among CD8+ T cells in the spleen and tumor tissue. C interferon-γ (IFN-γ), interleukin-2 receptor (IL-2Rα), interleukin-6 (IL-6), and interleukin-10 (IL-10) levels in blood were detected by enzyme-linked immunosorbent assay (ELISA). Data represent the mean ± standard deviation (SD) and were analyzed by one-way analysis of variance (ANOVA). *P < 0.05, ** P > 0.01, ***P > 0.001, **** P < 0.0001.
Fig. 8 Enhanced anti-tumor immune response by gut microbiota and short-chain fatty acids (SCFAs). A, B Flow cytometry to detect the immune cells in the spleen and tumors (n = 5 per group). Infiltration of CD45+ T cells, CD3+ T cells, CD8+ T cells, and the expression of tumor necrosis factor-α (TNF-α), granzyme B (GZMB) among CD8+ T cells in the spleen and tumor tissue. C interferon-γ (IFN-γ), interleukin-2 receptor (IL-2Rα), interleukin-6 (IL-6), and interleukin-10 (IL-10) levels in blood were detected by enzyme-linked immunosorbent assay (ELISA). Data represent the mean ± standard deviation (SD) and were analyzed by one-way analysis of variance (ANOVA). *P < 0.05, ** P > 0.01, ***P > 0.001, **** P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 9 Gut microbiota and short-chain fatty acids (SCFAs) enhance anti-tumor effects by modulating the gut microbial environment. A Histopathological changes of colon tissues were observed and scored under 5× and 20×. Based on the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) for Rats and Mice Pathology, the colon tissue pathology of the three groups was evaluated from two aspects: erosion or ulceration and inflammatory cell infiltration. Heatmap (B) and histogram (C) depict the gut microbiota composition across the three groups of mice. D, E Analysis of the differences in gut microbiota composition and dominant microbiota among the three groups. F Linear discriminant analysis effect size (LEfSe) analysis, with a Linear Discriminant Analysis (LDA) threshold of 4, identifies key microbiota taxa enriched in each group, visualized as colored nodes. These taxa significantly contribute to the intergroup differences. G The LDA discriminant histogram quantifies microbial taxa with significant effects across groups. With larger LDA scores indicating a greater influence of species abundance on group differences. Statistical differences were examined using one-way analysis of variance (ANOVA). *P < 0.05, ** P < 0.01, *** P < 0.001.
Fig. 9 Gut microbiota and short-chain fatty acids (SCFAs) enhance anti-tumor effects by modulating the gut microbial environment. A Histopathological changes of colon tissues were observed and scored under 5× and 20×. Based on the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) for Rats and Mice Pathology, the colon tissue pathology of the three groups was evaluated from two aspects: erosion or ulceration and inflammatory cell infiltration. Heatmap (B) and histogram (C) depict the gut microbiota composition across the three groups of mice. D, E Analysis of the differences in gut microbiota composition and dominant microbiota among the three groups. F Linear discriminant analysis effect size (LEfSe) analysis, with a Linear Discriminant Analysis (LDA) threshold of 4, identifies key microbiota taxa enriched in each group, visualized as colored nodes. These taxa significantly contribute to the intergroup differences. G The LDA discriminant histogram quantifies microbial taxa with significant effects across groups. With larger LDA scores indicating a greater influence of species abundance on group differences. Statistical differences were examined using one-way analysis of variance (ANOVA). *P < 0.05, ** P < 0.01, *** P < 0.001.CC BY-NC-ND · PubMed Central
Fig. 10 Gut microbiota influences the efficacy of chemo-immunotherapy combination through the production of short-chain fatty acids (SCFAs). Composition of gut microbiota altered in responders (R) and non-responders (NR) groups. In the R group, gut flora, including Escherichia, Bacteroides, Faecalibacterium, etc., produced more abundance of SCFAs through enhanced glycolysis. SCFAs promoted the induction of CD19+ B cells, CD3+ T cells, CD4+ T cells, CD8+ T cells, lymphocytes, and reduced the level of interleukin-2 receptor (IL-2R); therefore, they augmented the curative effect of chemo-immunotherapy combination on non-small cell lung cancer (NSCLC).
Fig. 10 Gut microbiota influences the efficacy of chemo-immunotherapy combination through the production of short-chain fatty acids (SCFAs). Composition of gut microbiota altered in responders (R) and non-responders (NR) groups. In the R group, gut flora, including Escherichia, Bacteroides, Faecalibacterium, etc., produced more abundance of SCFAs through enhanced glycolysis. SCFAs promoted the induction of CD19+ B cells, CD3+ T cells, CD4+ T cells, CD8+ T cells, lymphocytes, and reduced the level of interleukin-2 receptor (IL-2R); therefore, they augmented the curative effect of chemo-immunotherapy combination on non-small cell lung cancer (NSCLC).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Mann, P. C.. International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Standardized terminology of pathological lesions in rats and mice [Translated into Chinese]. China Agricultural Press (2019).

Cited by

See all 45

Metadata

Authors
Yang, Y., Ye, M., Song, Y., Xing, W., Zhao, X., Li, Y., Shen, J., Zhou, J., Arikawa, K., Wu, S., Song, Y., & Xu, N.
Affiliations
  • Fudan University (CN)
  • Shanghai Medical College of Fudan University (CN)
  • John H. Stroger, Jr. Hospital of Cook County (US)
Corresponding author
  • Song, Yijun
  • Wu, Shengdi
  • Song, Yuanlin
  • Xu, Nuo
Venue
npj Biofilms and Microbiomes
Published
2025-07-28
Volume
11
Issue
1
Pages
146-146
ISSN
2055-5008 (ISSN-L)
OpenAlex
W4412701897
Cited by
36
References
38
Citations by year
2026: 29 · 2025: 7
FWCI
10.82
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Biofilms and Microbiomes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Key R&D Plan (2020YFC2003700)
  • Shanghai Municipal Science and Technology Major Project (ZD2021CY001)
  • Science and Technology Commission of Shanghai Municipality (20Z11901000, 20DZ2261200, 20XD1401200, 22Y11900800)
  • Clinical Research Plan of SHDC (SHDC2020CR5010-002)
  • Shanghai Municipal Key Clinical Specialty (shslczdzk02201)
  • Shanghai Municipal Health Commission and Shanghai Municipal Administrator of Traditional Chinese Medicine (ZY(2021-2023)-0207-01)
  • National Natural Science Foundation of China (81401877, 82130001, and 82272243)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
gut microbiota, short-chain fatty acids, non-small cell lung cancer, chemoimmunotherapy, treatment response prediction, gut dysbiosis, Faecalibacterium, Subdoligranulum, Firmicutes, effector T cells, fecal microbiota transplantation, microbial biomarkers
MeSH terms
Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Aged, Animals, Antineoplastic Agents, Bacteria, Carcinoma, Non-Small-Cell Lung, Fatty Acids, Volatile, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, RNA, Ribosomal, 16S, Treatment Outcome, Mice, Metagenomics, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC. https://app.cochat.ai/papers/10.1038/s41522-025-00785-9
The paper
Yang, Y., Ye, M., Song, Y., Xing, W., Zhao, X., Li, Y., Shen, J., Zhou, J., Arikawa, K., Wu, S., Song, Y., & Xu, N. (2025). Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC. npj Biofilms and Microbiomes. https://doi.org/10.1038/s41522-025-00785-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.